NASDAQ$EXEL

Exelixis Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Exelixis reported strong Q3 2023 financial results, driven by the CABOMETYX® commercial franchise, and provided a corporate update.

Exelixis announced strong Q3 2023 financial results with total revenues of $471.9 million, compared to $411.7 million for the comparable period in 2022. Net product revenues were $426.5 million, an increase from $366.5 million in the same period of the prior year. GAAP net income was $1.0 million, or $0.00 per share, while non-GAAP net income was $32.1 million, or $0.10 per share.

  • Total revenues for Q3 2023 were $471.9 million, compared to $411.7 million for the comparable period in 2022.
  • Net product revenues for Q3 2023 were $426.5 million, compared to $366.5 million for the comparable period in 2022.
  • GAAP net income for Q3 2023 was $1.0 million, or $0.00 per share, compared to $73.2 million, or $0.23 per share for the comparable period in 2022.
  • Non-GAAP net income for Q3 2023 was $32.1 million, or $0.10 per share, compared to $102.0 million, or $0.32 per share for the comparable period in 2022.

Headline financials

Total Revenue

$472M

Previous: $412M+14.6%
EPS (adj)

$0.10

Previous: $0.31-67.7%
Research and Development Expenses

$333M

Previous: $199M+67.3%
Selling, General and Administrative Expenses

$138M

Previous: $115M+20.1%
Provision for Income Taxes

$4.8M

Previous: $18.8M-74.5%
Capital Expenditures

-$27.3M

Previous: -$26M-5.2%
Free Cash Flow

-$26.3M

Previous: $47.2M-155.7%
Net Income

$1.04M

Previous: $73.2M-98.6%
Operating Income

-$17.6M

Previous: $82.6M-121.3%
Gross Profit

$453M

Previous: $396M+14.3%
Cash & Equivalents

$1.1B

Previous: $675M+63.4%
Total Assets

$2.98B

Previous: $2.96B+0.5%
R&D Expense

$333M

No prior period
Stock-Based Comp

$40.5M

Previous: $37.3M+8.4%

Revenue & EPS history

Exelixis · Revenue · Quarterly

$472M

Q3 2023+14.6%vs Q3 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Exelixis · $469M total across 3 segments · Q3 2023

  • CABOMETYX Net Product Revenue
    $422M+16.8%
  • Collaboration Revenues
    $42.4M+23.2%
  • COMETRIQ Net Product Revenue
    $4.3M-15.7%

Forward guidance

Exelixis is providing the following updated financial guidance for fiscal year 2023:

Tailwinds

  • Total revenues $1.825 billion - $1.850 billion
  • Net product revenues $1.625 billion - $1.650 billion
  • Cost of goods sold4.0% - 5.0% of net product revenues
  • Research and development expenses (1)$1.050 billion - $1.075 billion
  • Selling, general and administrative expenses (2)$525 million - $550 million

Headwinds

  • Effective tax rate20% - 22%
  • Total revenues $1.825 billion - $1.850 billion
  • Net product revenues $1.625 billion - $1.650 billion
  • Research and development expenses (1) $1.050 billion - $1.075 billion
  • Selling, general and administrative expenses (2) $525 million - $550 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.5%

Avg return

Earnings day

+2.7%

Avg return

5 days after

+3.6%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+25.5%

Q3 2018

Best reaction

-12.0%

Q4 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.7%+11.9%+18.6%
Q4 2025-0.1%+2.2%-4.0%
Q3 2025+6.5%+9.3%+17.0%
Q1 2025+20.7%+20.9%+12.6%
Q4 2024-0.0%+6.7%+11.7%
Q3 2024+13.8%+19.7%+26.1%
Q2 2024+12.8%+14.7%+8.7%
Q1 2024-7.6%-7.7%-12.4%
Q4 2023-5.7%-5.5%+3.2%
Q3 2023-2.2%+1.2%+6.6%
Q2 2023+3.2%+2.8%+13.6%
Q1 2023+1.8%+0.8%+1.7%
Q4 2022+2.8%+1.6%-3.5%
Q3 2022+2.6%-0.7%+2.8%
Q2 2022-9.5%-9.6%-17.4%
Q1 2022+2.6%+3.8%-2.4%
Q4 2021+2.5%+2.7%+12.1%
Q3 2021-11.3%-10.8%-24.1%
Q2 2021+2.7%+2.5%+17.7%
Q1 2021+4.8%+3.0%-6.7%
Q4 2020-3.8%-4.5%+1.4%
Q3 2020-8.3%-6.0%-16.0%
Q2 2020-3.0%-6.0%-10.3%
Q1 2020+2.2%+1.4%-11.9%
Q4 2019-7.4%-7.9%-14.4%
Q3 2019-8.8%-5.0%-1.8%
Q2 2019-3.8%-6.7%-6.4%
Q1 2019+2.7%+5.0%-0.4%
Q4 2018+5.1%+6.1%+18.0%
Q3 2018+25.5%+22.3%+46.4%
Q2 2018+8.2%+1.2%-9.2%
Q1 2018+5.8%+5.8%-2.0%
Q4 2017-8.1%-18.4%-24.2%
Q3 2017+2.9%+10.4%+13.4%
Q2 2017-2.9%+0.8%+9.5%
Q1 2017+3.4%-3.2%-16.5%
Q4 2016-0.7%+6.4%-2.6%
Q3 2016+10.2%+15.4%+60.7%
Q2 2016+21.0%+19.5%+26.1%
Q1 2016+0.4%
Q4 2015-0.5%
Q3 2015-5.9%
Q2 2015-2.2%
Q1 2015+3.3%
Q4 2014-2.2%
Q3 2014+0.0%
Q2 2014-1.9%
Q1 2014-6.2%
Q4 2013-2.2%
Q3 2013-7.6%
Q2 2013-4.4%
Q1 2013+6.3%
Q4 2012-6.6%
Q3 2012-6.1%
Q2 2012-7.5%
Q1 2012-3.8%
Q1 2011-3.8%
Q4 2011+2.5%
Q4 2009+2.5%
Q3 2011+3.8%
Q3 2010+3.8%
Q2 2011-12.0%
Q4 2010-12.0%
Q2 2010-5.2%
Q1 2010+17.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro